Literature DB >> 25584008

Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study.

Jonathan D Wasserman1, Ana Novokmet2, Claudia Eichler-Jonsson2, Raul C Ribeiro2, Carlos Rodriguez-Galindo2, Gerard P Zambetti2, David Malkin2.   

Abstract

PURPOSE: Adrenocortical carcinoma (ACC) is a rare pediatric malignancy. It occurs in excess among individuals with the Li-Fraumeni syndrome, which results primarily from germline mutations in the TP53 gene. Prior series exploring frequencies of germline TP53 mutation among children with ACC have been small, geographically limited, or subject to referral bias. The functional consequence of mutations has not been related to phenotype. We provide a genotype-phenotype analysis of TP53 mutations in pediatric ACC and propose a model for tissue-specific effects based on adrenocortical ontogeny. PATIENTS AND METHODS: Eighty-eight consecutive, unrelated children with ACC, unselected for family history, underwent germline TP53 sequencing. Rate and distribution of mutations were identified. Functional analysis was performed for novel TP53 variants. Correlation with the International Agency for Research on Cancer p53 database further delineated mutational distribution, association with family history, and risk for multiple primary malignancies (MPMs).
RESULTS: Germline mutations were present in 50% of children. These mutations did not correspond to the conventional hotspot mutations. There was a wide range of mutant protein function. Patients bearing alleles encoding protein with higher functionality were less likely to have a strong family cancer history, whereas those with greater loss of function had MPMs and/or positive family history. In patients with MPMs, ACC was the most frequent initial malignancy. Finally, we demonstrated age-dependent rates of TP53 mutation positivity.
CONCLUSION: TP53 mutations are prevalent in children with ACC but decline with age. Mutations result in a broad spectrum of functional loss. Effect of individual mutations may predict carrier and familial disease penetrance with potentially broad implications for clinical surveillance and counseling.
© 2015 by American Society of Clinical Oncology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25584008      PMCID: PMC4517369          DOI: 10.1200/JCO.2013.52.6863

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  51 in total

Review 1.  The p53 mutation "gradient effect" and its clinical implications.

Authors:  Gerard P Zambetti
Journal:  J Cell Physiol       Date:  2007-11       Impact factor: 6.384

2.  SNP array profiling of childhood adrenocortical tumors reveals distinct pathways of tumorigenesis and highlights candidate driver genes.

Authors:  Eric Letouzé; Roberto Rosati; Heloisa Komechen; Mabrouka Doghman; Laetitia Marisa; Christa Flück; Ronald R de Krijger; Max M van Noesel; Jean-Christophe Mas; Mara A D Pianovski; Gerard P Zambetti; Bonald C Figueiredo; Enzo Lalli
Journal:  J Clin Endocrinol Metab       Date:  2012-04-26       Impact factor: 5.958

Review 3.  Differences in the molecular mechanisms of adrenocortical tumorigenesis between children and adults.

Authors:  André M Faria; Madson Q Almeida
Journal:  Mol Cell Endocrinol       Date:  2011-10-14       Impact factor: 4.102

4.  Concise handbook of familial cancer susceptibility syndromes - second edition.

Authors:  Noralane M Lindor; Mary L McMaster; Carl J Lindor; Mark H Greene
Journal:  J Natl Cancer Inst Monogr       Date:  2008

Review 5.  Towards an understanding of the role of p53 in adrenocortical carcinogenesis.

Authors:  Jonathan D Wasserman; Gerard P Zambetti; David Malkin
Journal:  Mol Cell Endocrinol       Date:  2011-09-10       Impact factor: 4.102

Review 6.  The International Pediatric Adrenocortical Tumor Registry initiative: contributions to clinical, biological, and treatment advances in pediatric adrenocortical tumors.

Authors:  Raul C Ribeiro; Emilia M Pinto; Gerard P Zambetti; Carlos Rodriguez-Galindo
Journal:  Mol Cell Endocrinol       Date:  2011-10-23       Impact factor: 4.102

7.  Childhood adrenocortical carcinoma as a sentinel cancer for detecting families with germline TP53 mutations.

Authors:  S S Choong; Z A Latiff; M Mohamed; L L W Lim; K S Chen; L Vengidasan; H Razali; E J Abdul Rahman; H Ariffin
Journal:  Clin Genet       Date:  2012-01-30       Impact factor: 4.438

8.  TP53 germline mutations in adult patients with adrenocortical carcinoma.

Authors:  Leonie J M Herrmann; Britta Heinze; Martin Fassnacht; Holger S Willenberg; Marcus Quinkler; Nicole Reisch; Martina Zink; Bruno Allolio; Stefanie Hahner
Journal:  J Clin Endocrinol Metab       Date:  2011-12-14       Impact factor: 5.958

9.  Identification of a novel TP53 germline mutation E285V in a rare case of paediatric adrenocortical carcinoma and choroid plexus carcinoma.

Authors:  A Russell-Swetek; A N West; J E Mintern; J Jenkins; C Rodriguez-Galindo; R Ribeiro; G P Zambetti
Journal:  J Med Genet       Date:  2008-09       Impact factor: 6.318

10.  Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer.

Authors:  Sandra Costa; Daniela Pinto; Deolinda Pereira; Helena Rodrigues; Jorge Cameselle-Teijeiro; Rui Medeiros; Fernando Schmitt
Journal:  BMC Cancer       Date:  2008-01-29       Impact factor: 4.430

View more
  54 in total

1.  Association Between the Oligomeric Status of p53 and Clinical Outcomes in Li-Fraumeni Syndrome.

Authors:  Nicholas W Fischer; Aaron Prodeus; James Tran; David Malkin; Jean Gariépy
Journal:  J Natl Cancer Inst       Date:  2018-12-01       Impact factor: 13.506

2.  The cancer-associated, gain-of-function TP53 variant P152Lp53 activates multiple signaling pathways implicated in tumorigenesis.

Authors:  Siddharth Singh; Manoj Kumar; Sanjeev Kumar; Shrinka Sen; Pawan Upadhyay; Sayan Bhattacharjee; Naveen M; Vivek Singh Tomar; Siddhartha Roy; Amit Dutt; Tapas K Kundu
Journal:  J Biol Chem       Date:  2019-07-31       Impact factor: 5.157

3.  A Novel TP53 Mutation Associated with TWIST1 and SIP1 Expression in an Aggressive Adrenocortical Carcinoma.

Authors:  Daniel Bulzico; Davi Coe Torres; Gerson Moura Ferreira; Bruno Ricardo Barreto Pires; Paulo Antônio Silvestre de Faria; Rocio Hassan; Eliana Abdelhay; Mario Vaisman; Leonardo Vieira Neto
Journal:  Endocr Pathol       Date:  2017-12       Impact factor: 3.943

4.  Pediatric Cancer Genetics Research and an Evolving Preventive Ethics Approach for Return of Results after Death of the Subject.

Authors:  Sarah Scollon; Katie Bergstrom; Laurence B McCullough; Amy L McGuire; Stephanie Gutierrez; Robin Kerstein; D Williams Parsons; Sharon E Plon
Journal:  J Law Med Ethics       Date:  2015       Impact factor: 1.718

Review 5.  Adrenocortical tumorigenesis: Lessons from genetics.

Authors:  Crystal D C Kamilaris; Fady Hannah-Shmouni; Constantine A Stratakis
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2020-05-23       Impact factor: 4.690

Review 6.  Advances in the Treatment of Pediatric Bone Sarcomas.

Authors:  Patrick J Grohar; Katherine A Janeway; Luke D Mase; Joshua D Schiffman
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017

7.  A Rare TP53 Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers.

Authors:  Jacquelyn Powers; Emilia M Pinto; Thibaut Barnoud; Jessica C Leung; Tetyana Martynyuk; Andrew V Kossenkov; Aaron H Philips; Heena Desai; Ryan Hausler; Gregory Kelly; Anh N Le; Marilyn M Li; Suzanne P MacFarland; Louise C Pyle; Kristin Zelley; Katherine L Nathanson; Susan M Domchek; Thomas P Slavin; Jeffrey N Weitzel; Jill E Stopfer; Judy E Garber; Vijai Joseph; Kenneth Offit; Jill S Dolinsky; Stephanie Gutierrez; Kelly McGoldrick; Fergus J Couch; Brooke Levin; Morris C Edelman; Carolyn Fein Levy; Sheri L Spunt; Richard W Kriwacki; Gerard P Zambetti; Raul C Ribeiro; Maureen E Murphy; Kara N Maxwell
Journal:  Cancer Res       Date:  2020-07-16       Impact factor: 12.701

8.  Survival in males with glioma and gastric adenocarcinoma correlates with mutant p53 residual transcriptional activity.

Authors:  Nicholas W Fischer; Aaron Prodeus; Jean Gariépy
Journal:  JCI Insight       Date:  2018-08-09

9.  Is there a role for epithelial-mesenchymal transition in adrenocortical tumors?

Authors:  Daniel Bulzico; Paulo Antônio Silvestre de Faria; Camila Bravo Maia; Marcela Pessoa de Paula; Davi Coe Torres; Gerson Moura Ferreira; Bruno Ricardo Barreto Pires; Rocio Hassan; Eliana Abdelhay; Mario Vaisman; Leonardo Vieira Neto
Journal:  Endocrine       Date:  2017-09-08       Impact factor: 3.633

10.  Identification of Clinical and Biologic Correlates Associated With Outcome in Children With Adrenocortical Tumors Without Germline TP53 Mutations: A St Jude Adrenocortical Tumor Registry and Children's Oncology Group Study.

Authors:  Emilia Modolo Pinto; Carlos Rodriguez-Galindo; Stanley B Pounds; Lei Wang; Michael R Clay; Geoffrey Neale; Elizabeth A R Garfinkle; Catherine G Lam; Carolyn Fein Levy; Alberto S Pappo; Gerard P Zambetti; Raul C Ribeiro
Journal:  J Clin Oncol       Date:  2017-10-23       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.